Join the fight against Alzheimer’s disease
Effects of ACI-24.060 in subjects with prodromal Alzheimer’s disease and in adults with Down syndrome
(The ABATE Study)
The ABATE Study is testing a vaccine for Alzheimer’s disease in people with Down syndrome.
What is the ABATE Study?
People with Down syndrome often get Alzheimer’s disease (a type of dementia) when they get older. Dementia is a disease that causes memory loss and other thinking problems. Dementia due to Alzheimer’s occurs when a protein called amyloid builds up in the brain.
About 80 people with Down syndrome will take part in the ABATE Study. The study is testing a vaccine for Alzheimer’s disease in people with Down syndrome. We want to see:
- If the vaccine is safe
- How the vaccine works inside the body
- If it helps get rid of amyloid buildups
- If it slows down memory loss and thinking problems
Who is eligible for the ABATE Study?
You may be able to join this study if you:
- Have Down syndrome
- Are between 35 and 50 years old
- Have a study partner
Further information
To learn more, visit the Abate Study website and/or contact the nearest research centre (details below).
Research centres
For people living in London, South East and South-West England:
Please contact Professor Strydom’s team in London on downsyndrome@kcl.ac.uk.
For people living in Eastern England, East and Central Midlands and Yorkshire:
Please contact Dr Shahid Zaman’s team in Cambridge and Peterborough NHS Foundation Trust (Windsor Research Units) on 01223 219531 or wru@cpft.nhs.uk.
For people living in West Midlands and the North West of England:
Please contact Dr. Vanessa Raymont’s team in Oxford NHS Foundation Trust on 01865 902135 or oxfordhealth.crf@nhs.net.
People living outside of the above-mentioned regions (e.g. Wales) should contact whichever centre works best for them as may subjects who for any reason (eg with pre-existing connections) would prefer to attend a particular centre.
About the researchers
Professor Strydom has been working on understanding issues related to Alzheimer’s disease in people with Down syndrome for many years, including how signs may be different from the general population, how to best diagnose the condition in people with Down syndrome, and use of new markers using blood tests to track change over time so that these can be used in clinics and in treatment trials. He leads the LonDowns and Go-DS21 research programs at King’s College London (KCL).
He runs the NDD clinical trials centre at King’s College London which specialises in conducting treatment trials in people with neurodevelopmental conditions such as Down syndrome.
Dr. Zaman is an honorary consultant psychiatrist working with adults with intellectual disability in Cambridgeshire, a neuroscientist, and an associate Professor in Psychiatry of Intellectual Disability at the University of Cambridge. He is the lead of the Cambridge Intellectual Disability Research Group at the Department of Psychiatry.
Dr Raymont is a Consultant Psychiatrist and Senior Clinical Researcher at Oxford University. She works in traumatic brain injury and dementia and has 20 years of experience in clinical trials. She is an associate director of Dementia Platforms UK and is deputy chair of the NIHR Dementia Translational Research Collaboration.